2026-01-06 - Analysis Report
Here's a comprehensive analysis of Intuitive Surgical (ISRG) based on the provided data.

**1) Return Comparison and Alpha/Beta Analysis**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical systems and related instruments and accessories.
*   **Return Comparison:**
    *   ISRG Cumulative Return: 78.60%
    *   S&P 500 (VOO) Cumulative Return: 91.00%
    *   Divergence: -12.40%
    *   Relative Divergence: 29.2
*   **Analysis:** ISRG has underperformed the S&P 500 over the period examined, with a final cumulative return 12.4% lower. The relative divergence of 29.2 indicates that the current divergence is closer to its historical minimum compared to its maximum.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 49.0% | 29.0% | 45.0% | 1.2 | 57.7 |
| 2017-2019  | 40.0% | 29.0% | 23.0% | 1.4 | 71.2 |
| 2018-2020  | -8.0% | 29.0% | -29.0% | 1.2 | 98.5 |
| 2019-2021  | 26.0% | 21.1% | -17.0% | 1.2 | 129.8 |
| 2020-2022  | -18.0% | 48.9% | -16.0% | 1.2 | 95.9 |
| 2021-2023  | -12.0% | 48.9% | -13.0% | 1.4 | 121.9 |
| 2022-2024  | 35.0% | 38.0% | 16.0% | 1.3 | 188.6 |
| 2023-2025  | 60.0% | 28.0% | -2.0% | 1.2 | 204.6 |

*   **CAGR:** Fluctuating significantly, showing periods of strong growth and decline.  The recent CAGR of 60.0% for 2023-2025 is impressive.
*   **MDD:** Maximum Drawdown shows the potential downside risk. Notice the 48.9% MDD for 2020-2022 and 2021-2023 suggesting significant volatility during those periods.
*   **Alpha:**  Indicates performance relative to the market (S&P 500). Negative alpha in several periods (2018-2020, 2019-2021, 2020-2022, 2021-2023, 2023-2025) indicates underperformance relative to the market.
*   **Beta:** Beta values around 1.2 to 1.4 indicate that ISRG's price is more volatile than the market.
*   **Cap(B):** Market capitalization growth is significant over the analyzed period.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 561.98
*   **Last Market Data:** Price: 566.38, Previous Close: 561.98, Change: 0.78
*   **5-day SMA:** 570.84
*   **20-day SMA:** 565.42
*   **60-day SMA:** 540.17

*   **Analysis:** The current price is below the 5-day and 20-day SMAs, but above the 60-day SMA. This suggests a possible short-term downtrend or consolidation phase after a longer-term uptrend. The last market data shows a slight positive change, indicating a minor rebound.

**3) RSI, PPO, and Expected Return**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 60.21
*   **PPO:** -0.24
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent Divergence Change:** -2.3 (Short-term Decline)
*   **Expected Return:** 4.3%

*   **Analysis:**
    *   **MRI:** The MRI of 0.8 suggests a medium level of risk and a recommendation for investment.
    *   **RSI:** An RSI of 60.21 is neutral, indicating neither overbought nor oversold conditions.
    *   **PPO:** A slightly negative PPO (-0.24) suggests a potential weakening of the upward momentum.
    *   **Hybrid Signal:**  The signal suggests to buy 90% of cash with 1 shares in the current decision.
    *   **Recent Divergence Change:** The negative divergence change suggests a recent underperformance compared to the S&P 500.
    *   **Expected Return:**  A 4.3% expected return suggests positive growth potential over a longer-term investment horizon.

**4) Recent News & Significant Events**

*   **Truist and RBC Capital Raise Price Targets:** Positive signal indicating analyst confidence.
*   **Intuitive Surgical (ISRG) Valuation Check:** Potentially concerning, as it suggests the stock might be richly valued. Investors should delve deeper into the rationale.
*   **Intuitive Surgical Stock Hits Key Support - Buying Opportunity?:** Suggests a possible entry point for investors.
*   **Intuitive Surgical Stock Falls Today:** Indicates recent price weakness, potentially related to valuation concerns or market factors.
*   **Stanley Laman Group Ltd. Has $6.02 Million Stock Position:** Positive signal, showing institutional investment.
*   **Should You Buy Shares of Intuitive Surgical in December?:** Focus on investment suitability given the company's prospects.

**4-2) Analyst Opinions**

*   **Consensus:** No rating given.
*   **Target Price:** Average: 600.98, High: 700.00, Low: 378.00

*   **Analysis:** Analyst target prices show a wide range of opinions, from a low of $378.00 to a high of $700.00. The average target price of $600.98 suggests potential upside from the current price, but the wide range indicates uncertainty.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-10-22 | 1.98 | 2.51 B$   |
| 2025-07-23 | 1.84 | 2.44 B$   |
| 2025-04-23 | 1.95 | 2.25 B$   |
| 2024-10-18 | 1.59 | 2.04 B$   |
| 2025-10-22 | 1.59 | 2.04 B$   |

*   **Analysis:**
    *   **EPS:** Shows a general upward trend in earnings per share over the past year.
    *   **Revenue:**  Shows consistent growth in revenue over the same period. This indicates strong business performance.

**6) Financial Information: Revenue, Profitability, and Capital**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $2.51B | 66.36% |
| 2025-06-30 | $2.44B | 66.31% |
| 2025-03-31 | $2.25B | 64.69% |
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $16.93B | 4.16% |
| 2025-06-30 | $17.85B | 3.69% |
| 2025-03-31 | $17.11B | 4.08% |
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |

*   **Analysis:**
    *   **Revenue:** Consistent growth trend, confirming the earnings analysis.
    *   **Profit Margin:** Extremely high and stable, suggesting a strong competitive advantage and efficient operations.
    *   **Equity:** Growing steadily, reflecting retained earnings and balance sheet strength.
    *   **ROE:** A bit volatile but generally positive, indicating that the company is generating returns on its equity.

**7) Comprehensive Analysis**

*   **Summary:**
    *   ISRG has underperformed the S&P 500 recently, but shows strong revenue and profit margin.
    *   Technical indicators are mixed, suggesting a possible consolidation phase.
    *   Analyst opinions are divided, with a wide range of target prices.
    *   Recent news highlights both positive developments (raised price targets, institutional investment) and potential concerns (valuation, stock price decline).
    *   Long-term growth potential is supported by strong financials and industry leadership.
*   **Investment Recommendation (Based on Data Provided):**
    *   The MRI suggests a medium investment recommendation.
    *   Considering the valuation concerns, recent stock price decline, and mixed analyst opinions, a cautious approach is warranted. Investors might consider a partial buy, with the intention of averaging down if the stock price weakens further. Monitoring upcoming earnings releases and industry news is crucial.
*   **Key Considerations:**
    *   **Valuation:**  Pay close attention to valuation metrics and growth prospects to ensure the stock price is justified.
    *   **Competition:**  The robotic surgery market is becoming increasingly competitive. Monitor ISRG's ability to maintain its market share and technological advantage.
    *   **Regulatory Environment:**  Changes in healthcare regulations could impact ISRG's business model.
    *   **Short-term Downtrend:** Consider waiting for stronger signals that the short-term downtrend is reversing before making a significant investment.

**Disclaimer:** This analysis is based solely on the data provided and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.